Suppressive effects of conversion from mycophenolate mofetil to everolimus for the development of cardiac allograft vasculopathy in maintenance of heart transplant recipients  by Watanabe, Takuya et al.
International Journal of Cardiology 203 (2016) 307–314
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdSuppressive effects of conversion from mycophenolate mofetil to
everolimus for the development of cardiac allograft vasculopathy in
maintenance of heart transplant recipients☆,☆☆Takuya Watanabe a,b, Osamu Seguchi a, Kunihiro Nishimura c, Tomoyuki Fujita d, Yoshihiro Murata a,e,
Masanobu Yanase a, Takuma Sato a, Haruki Sunami a, Seiko Nakajima a, Eriko Hisamatsu a, Takamasa Sato a,
Kensuke Kuroda a, Michinari Hieda f, Kyoichi Wada g, Hiroki Hata d, Hatsue Ishibashi-Ueda h,
Yoshihiro Miyamoto b,c, Norihide Fukushima a, Junjiro Kobayashi d, Takeshi Nakatani a,⁎
a Department of Transplantation, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
b Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
c Department of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
d Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
e Department of Cardiology, Kumiai Kosei Hospital, Takayama, Gifu, Japan
f Department of Cardiovascular Rehabilitation, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
g Department of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
h Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Osaka, JapanAbbreviations: %PVI, percent plaque volume index; 3D
virus; CNIs, calcineurin inhibitors; EEM, external elastic m
and Lung Transplantation; LVI, lumen volume index; MIT
and Cardiovascular Center; PVI, plaque volume index; VV
☆ All authors take responsibility for all aspects of the re
☆☆ Acknowledgement of grant support: The interpretat
Cerebral and Cardiovascular Center. The writing of the re
Aid for Young Scientist (B), Number 15K21697.
⁎ Corresponding author at: Department of Transplanta
E-mail address: nakatani.takeshi.hp@mail.ncvc.go.jp (
http://dx.doi.org/10.1016/j.ijcard.2015.10.082
0167-5273/© 2015 The Authors. Published by Elsevier Irea b s t r a c ta r t i c l e i n f oArticle history:
Received 10 June 2015
Received in revised form 26 September 2015
Accepted 12 October 2015
Available online 23 October 2015
Keywords:
Heart transplantation
Cardiac allograft vasculopathy
Everolimus
Three-dimensional intravascular ultrasoundBackground:Whether converting to everolimus (EVL) from mycophenolate mofetil (MMF) during the mainte-
nance period after heart transplantation (HTx) reduces cardiac allograft vasculopathy (CAV) progression remains
unclear. We sought to determine the effect of converting from MMF with standard-dose calcineurin inhibitors
(CNIs) to EVL with low-dose CNIs on CAV progression.
Methods:We retrospectively reviewed the medical records of 63 HTx recipients who survived at least at 1 year
after HTx. Twenty-four recipients were converted from MMF to EVL (EVL group, 2.2 ± 2.3 years after HTx),
while 39 recipientsweremaintained onMMF (MMF group, 2.4± 2.2 years after HTx). The EVL group underwent
three-dimensional intravascular ultrasound (3D-IVUS) analysis before and 1 year after conversion to EVL, and
these data were compared with data from 2 consecutive IVUS in the MMF group.
Results: IVUS indices in the EVL group at 1 year after conversion did not show increased CAV development,
whereas a signiﬁcant increase in %plaque volume (p = 0.006) and decrease in lumen volume (p b 0.001) were
observed in the MMF group. EVL conversion was signiﬁcantly associated with smaller increases in %plaque vol-
ume (p = 0.004) and smaller decreases in lumen volume (p = 0.017). IVUS indices in the late EVL conversion
group (≥2 years) also did not exhibit increased CAV development, while those in the MMF group did.
Conclusions: Conversion to EVL from MMF in maintenance periods after HTx may decrease the rate of CAV pro-
gression based on IVUS indices.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).-IVUS, three-dimensional intravascular ultrasound; AZA, azathioprine; CAV, cardiac allograft vasculopathy; CMV, cytomegalo-
embrane; EVL, everolimus; GFR, glomerular ﬁltration rate; HTx, heart transplantation; ISHLT, International Society of Heart
, maximal intimal thickness; MMF, mycophenolate mofetil; mTOR, mammalian target of rapamycin; NCVC, National Cerebral
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Cardiac allograft vasculopathy (CAV) is the leading cause of late
morbidity and mortality in heart transplant recipients, accounting for
one-third of all-cause mortality at 5 years [1]. The pathophysiology of
CAV is closely linked to both immunologic factors, such as alloreactive
T-cell and antibody activation, and non-immunologic factors, including
pre-transplant coronary artery disease, cytomegalovirus (CMV) infec-
tion, older age of the donor and recipient, recipient's conventional risk
factor (e.g. hyperlipidemia, hypertension and diabetes mellitus) and is-
chemia/reperfusion injury [2]. This complex etiology makes it difﬁcult
to prevent and suppress the development of CAV.
Immunosuppression after heart transplantation (HTx) has tradition-
ally consisted of calcineurin inhibitors (CNIs) combined with mycophe-
nolate mofetil (MMF) or azathioprine (AZA) and corticosteroids [1].
Mammalian target of rapamycin (mTOR) inhibitors, the novel immuno-
suppressants such as everolimus (EVL) and sirolimus, are expected to
suppress CAV progression [3,4]. Previous studies have examined the in-
ﬂuence of mTOR inhibitors on CAV by comparing them with various
baseline immunosuppressive drugs, such as AZA [4], AZA and MMF
[3–5], CNI-free [6,7], and add-on regimens [8]. However, concomitant
immunosuppression with EVL may affect the suppressive effects of
EVL on CAV progression [8]. Recently, MMF has replaced AZA due to
inferior outcomes [9], and so a direct comparison between MMF and
EVL is required [10,11]. Recent clinical trials on de novo heart transplant
recipients have indicated that EVL with reduced-dose CNIs is more ef-
fective than MMF with standard-dose CNIs for suppressing ﬁrst-year
CAV progression after HTx [10,11]. However, the effects of converting
to EVL from MMF in maintenance periods after HTx are still controver-
sial [3,5–8]; furthermore, the underlying mechanism for the suppres-
sive effect of EVL on CAV progression remains unclear [10].
The aim of the present studywas to elucidate the effect of converting
from MMF with standard-dose CNIs to EVL with low-dose CNIs on
CAV progression using three-dimensional intravascular ultrasound
(3D-IVUS).
2. Methods
2.1. Patient management and selection
We retrospectively reviewed the medical records of all post-HTx recipients at the
National Cerebral and Cardiovascular Center (NCVC) in Japan between July 1993 and
March 2013.
All de novo heart transplant recipients in our institution received triple immunosup-
pressive therapy consisting of CNIs (i.e., cyclosporine or tacrolimus), MMF, and corticoste-
roids [12]. We regulated immunosuppressive drug dosage based on blood trough
concentrations. Standard target trough levels were as follows: cyclosporine,
350–450 ng/mL for the ﬁrst month, 250–350 ng/mL between 1 and 3 months,
200–300 ng/mL between 3 and 12 months, and 100–250 ng/mL after the 1-year follow-
up; tacrolimus, 9–12 ng/mL for the ﬁrst 3 months, 8–9 ng/mL between 3 and 6 months,
and 6–8 ng/mL after the 6-month follow-up. Tacrolimus was used as an alternative to cy-
closporine as the primary immunosuppressant beginning in 2005.
Since 2007, we have primarily considered converting fromMMF with standard-dose
CNIs to EVL with low-dose CNIs for the following recipients: 1) recipients with impaired
renal function (glomerular ﬁltration rate [GFR] b60 mL/min/1.73 m2); 2) those with in-
creases in or an initially large maximal intimal thickness (MIT) on routine IVUS examina-
tions; and 3) those with MMF-related leukopenia. According to our protocol for EVL
conversion with low-dose CNIs, the standard target trough levels were as follows: EVL,
6–8 ng/mL; reduced-dose cyclosporine, 50% of standard blood concentrations; and
reduced-dose tacrolimus, 3–4 ng/mL. The conversion to EVL from MMF was initiated
with EVL 1.0–1.5mg/day while MMFwas withdrawn. The trough levels of EVL were eval-
uated at 1 week after initiation. Once target trough levels of EVL (6–8 ng/mL) were
achieved, the tacrolimus or cyclosporine dose was reduced to obtain target trough levels
[13].
Routine endomyocardial biopsies were performed weekly for 3 weeks after HTx,
every 2 weeks from 3 weeks to 2 months, at 3 months, every 1.5 months from 3 months
to 6 months, every 3 months from 6months to 12months, and then at 6-month intervals
until the end of theﬁfth year, afterwhichwe performed endomyocardial biopsy every year.
An International Society of Heart and Lung Transplantation (ISHLT) grade of 2R or greater
acute cellular rejection on routine endomyocardial biopsywas treatedwith augmented im-
munosuppression and intravenous steroids [12,14,15]. Follow-up endomyocardial biopsies
were performed at 14 to 21 days in treated cases.Coronary angiography and IVUS examinationswere performed 5–12 weeks after HTx
and repeated to evaluate CAV every year. Coronary angiography was used to classify the
severity of CAV as ISHLT CAV 0 (not signiﬁcant), CAV 1 (mild), CAV 2 (moderate), or
CAV 3 (severe) on the basis of the ISHLT guidelines [16]. A 40-MHzmechanical ultrasound
transducer (View it®, Terumo, Tokyo, Japan)was advanced into a distal portion of the left
anterior descending artery. Continuous ultrasound imaging was acquired at a constant
rate of 1.0 mm/s to evaluate the coronary artery. Images were digitized for analysis by a
researcher (T.W.) who was blinded to the clinical characteristics and treatment status of
the patients. IVUS imageswere stored on S-VHS tapes for ofﬂine 3D IVUS analysis (Nicoras
T2000® Ver. 2.1, Terumo, Tokyo, Japan). Using cross-sectional IVUS images, we compared
changes in the MIT, which is known to impact long-term outcome after HTx [17–19], and
coronary vessel, plaque, and lumen volumes based on 3D-IVUS images in both the EVL and
MMF groups.
Seventy-four recipients who survived more than 1 year post-HTx were initially
screened for inclusion (Fig. 1). Of these, 11 recipients were excluded because they lacked
data from two consecutive IVUS studies. Of the remaining 63 recipients, 24 were convert-
ed from MMF with standard-dose CNIs to EVL with reduced-dose CNIs (EVL group). Of
these, 17 recipients (70.8%) were converted to EVL because of CAV development, and
ﬁve (20.8%) and two recipients (8.3%) were converted to EVL because of CNI-induced ne-
phropathy and MMF-related leukopenia, respectively. The other 39 recipients remained
on MMF with standard-dose CNIs (MMF group). Baseline characteristics of the recipients
included in this studywere collected at “study entry,”whichwasdeﬁned as the time of the
earlier of the twomost recent consecutive IVUS examinations in theMMFgroup and as the
time of the last IVUS examination before conversion in the EVL group. We analyzed data
from the two most recent consecutive IVUS examinations to include all recipients who
continued taking MMF as the control group. In the EVL group, IVUS data before EVL con-
version (study entry) and at the 1-year follow-up after conversion were analyzed. There-
fore, changes in IVUS parameters before and after conversion in the EVL group were
comparedwith changes in the parameters of the twomost recent consecutive IVUS exam-
inations in theMMF group. There were no signiﬁcant differences in the length of time be-
tweenHTx and study entry between the two groups (mean, 2.2 years after HTx for the EVL
group [range, 0.1–9.0 years] andmean, 2.4 years for theMMF group [range, 0.1–7.9 years],
p=0.614). To account for the timing of EVL conversion, study subjectswere sub-classiﬁed
into two groups according to the length of time between HTx and study entry. The “early”
cohort included subjects enrolled within 2 years post-HTx, and the “late” cohort included
the other subjects, who were enrolled more than 2 years post-HTx.
Because 14 recipients (7 in each group) underwent HTx in other countries, detailed
information on their donors (i.e., donor age, sex, status of CMV infection mismatch, and
cold ischemia time) were unavailable. In Japan, the Organ Transplant Law was enacted
in October 1997 [12,20], and the ﬁrst HTx in Japan was performed in February 1999
from a brain-dead donor in accordance with this law. From then until March 2013, 185
HTxs were performed in Japan, including 54 cases at our institute. In the present study,
we included 49 of those 54 patients who underwent HTx at our institute and 14 recipients
who underwent HTx in the United States and Germany on the basis of ofﬁcial procedures
between 1993 and 2009. The ethics committee of the NCVC of Japan approved this study.
Informed consent was obtained from all participants (IRB number M25-020 at NCVC).
2.2. Intravascular ultrasound measurements (Fig. 2)
We compared changes in IVUS data obtained at study entry and at the 1-year follow-
up between both groups. Cross-sectional images of the left anterior descending artery
spaced precisely 1 mm apart were selected for measurement. The maximum lengthmea-
sured was 50 mm of the left anterior descending artery, from the distal portion to the os-
tium. MIT was measured at the site with the greatest intimal thickness in the observed
length. Plaque area was deﬁned as the difference between the area occupied by the
lumen and external elastic membrane (EEM) borders. Volumetric analyses were calculat-
ed as the summation of each area (vessel, plaque, and lumen). Each volumewas standard-
ized to account for differences in segment length between different subjects (vessel,
plaque, and lumen volume indexes; VVI, PVI and LVI, respectively), and was calculated
as: volumetric value/measured length (mm3/mm). Percent plaque volume index (%PVI)
was calculated as: (PV/VV) × 100%. Change in percent plaque volume was calculated as:
(percent plaque volume at follow-up) − (percent plaque volume at study entry). In
order to adjust for differences in the initial IVUS data between the EVL and MMF groups,
relative changes for each volumetric data measure were calculated as: [(volumetric
index at follow-up− volumetric index at entry) / (volumetric index at entry)] × 100%.
2.3. Statin therapy
Statin therapy was generally initiated within 2 months after HTx for all post-
transplant recipients, regardless of cholesterol level, except for recipients who experi-
enced adverse effects due to statin therapy. Pravastatin was generally used [21], but if
the lipid proﬁle worsened or if CAV progression was observed with conventional statin
use, the statin dosage was increased or pravastatin was exchanged for a more powerful
agent (i.e., a “strong statin”).We used atorvastatin, rosuvastatin, and pitavastatin as strong
statins. Doses of at least 20 mg/day for pravastatin, 20 mg/day for atorvastatin, 5 mg/day
for rosuvastatin, and 4 mg/day for pitavastatin were classiﬁed as “high-dose” statins.
“Intensive statin therapy” was deﬁned as follows: (1) initiating statin therapy during the
study period in recipients who did not take statins at study entry, (2) increasing the statin
dosageduring the study period, and (3) converting to a strong statin frompravastatin dur-
ing the study period.
Fig. 1. Study ﬂow-chart. EVL = everolimus; HTx = heart transplantation; IVUS = intravascular ultrasound; MMF =mycophenolate mofetil.
Fig. 2.Deﬁnition of volumetric indices in intravascular ultrasound (IVUS) analyses. (A) An-
giography; (B) Two-dimensional IVUS analyses; (C) Three-dimensional IVUS analyses.
EEM = external elastic membrane; LAD = left anterior descending artery; LCX = left
circumﬂex artery; LMT= leftmain trunk; LVI= lumen volume index;MIT=maximal in-
timal thickness; %PVI=percent plaque volume index; PVI=plaque volume;VVI=vessel
volume index.
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Data are expressed asmeans± standard deviations for normally distributed continu-
ous variables, medians with interquartile ranges for non-normally distributed continuous
variables, and numbers (percentages) for categorical variables. The chi-squared test was
used to test for differences in categorical variables between groups. Comparisons between
study entry and follow-up IVUS data were determined with paired t-tests or Wilcoxon
signed rank tests within each treatment group. Changes in volumetric indices between
study entry and the 1-year follow-up were treated as categorical variables by deﬁning
themedian value as the cut-off point for relative changes in each volumetric IVUS param-
eter (−4.3%, 4.8%, 0.7% and−3.9%, for the changes in vessel, plaque, percent plaque, and
lumen volume index, respectively). Regarding changes inMIT, a cut-off value of a 0.3-mm
increase was chosen. The associations between change in IVUS parameters and EVL con-
version were investigated using a logistic regression analysis. A multivariable logistic re-
gression analysis was conducted using the recipients' age, sex, strong statin use at the 1-
year follow-up, intensive statin therapy, and time since HTx forModel 1 and the variables
with p-values b 0.05 in comparison between the two groups as shown in Table 1 forModel
2. A p-value b 0.05 was considered signiﬁcant. All analyses were performed using com-
mercial software (STATA® version 13, Stata Corporation, College Station TX, USA).
3. Results
3.1. Baseline clinical demographic
Table 1 shows baseline demographics, medications, and laboratory
data for both groups. The prevalence of previous hypertension
(p = 0.038) and antiplatelet therapy (p = 0.044) at study entry
were signiﬁcantly higher in the MMF group. Serum hemoglobin A1c
level was signiﬁcantly higher in the EVL group (p= 0.019). Renal func-
tion, whichwas assessed by creatinine value and estimated GFR (eGFR)
[22], was comparable between the two groups.
Regarding statin therapy (Table 2), there were no signiﬁcant differ-
ences between groups with respect to statin dose and type at study
entry. However, the EVL group had a higher rate of strong statins replac-
ing pravastatin at the 1-year follow-up (p=0.005), as four recipients in
the EVL group and two in the MMF group had been converted from
pravastatin to a strong statin by the 1-year follow-up. Additionally,
the EVL group had a higher incidence of intensive statin therapy at the
1-year follow-up (p = 0.021).
3.2. Severity of CAV at study entry
The severity of CAV on coronary angiography at study entry was
comparable between the two groups (p=0.256); 16 (66.7%) recipients
were graded as CAV 0 and 8 (33.3%) as CAV 1 in the EVL group, and 31
(79.4%) recipients were graded as CAV 0 and 8 (20.5%) as CAV 1 in the
MMF group. On the other hand, the prevalence of CAV determined by
IVUS (deﬁned as MIT N 0.5 mm) was higher in the EVL group than in
the MMF group (91.7% vs. 56.4%, p = 0.003).3.3. IVUS measurements in the EVL and MMF groups
Table 3 summarizes the IVUS measurements at study entry and at
the 1-year follow-up for the two groups. CAV on IVUS was more devel-
oped in the EVL group than in theMMF group at study entry, as indicat-
ed by signiﬁcantly greater PVI, %PVI, andMIT (all p b 0.001). LVIwas 20%
Table 1
Clinical characteristics, medications and laboratory data at study entry.
Variable EVL group,
n = 24
MMF group,
n = 39
p
value
Donor age, years 41.0 ± 15.7 35.1 ± 12.5 0.130
Male donor, n (%) 14 (70.0) 18 (52.9) 0.218
Recipient age, years 36.5 (26.2–46.4) 33.9 (21.7–44.3) 0.581
Male recipient, n (%) 20 (83.3) 28 (71.8) 0.296
Time since HTx, years 2.2 ± 2.3 2.4 ± 2.2 0.614
Time since HTx, years 1.1 (0.3–3.1) 2.9 (0.2–4.0) 0.966
CMV mismatch (D+/R−),
n (%)
3 (17.7) 6 (18.8) 0.924
Cold ischemic time, min 214.0
(179.0–231.0)
207.0
(183.0–218.5)
0.462
VAD before HTx, n (%) 22 (91.7) 33 (84.6) 0.414
Primary reason for HTx
Non-ICM, n (%) 24 (100) 37 (94.9) 0.260
BMI, kg/m2 21.4 (19.7–23.1) 19.7 (17.8–22.8) 0.240
Past medical history before
HTx
Hypertension, n (%) 2 (8.3) 12 (30.8) 0.038
Hyperlipidemia, n (%) 4 (16.7) 14 (35.9) 0.101
Diabetes mellitus, n (%) 3(12.5) 8 (20.5) 0.416
Prior smoking history, n (%) 10 (41.7) 12 (30.8) 0.378
PRA class I ≥ 10, n (%) 4 (16.7) 6 (15.4) 0.892
PRA class II ≥10, n (%) 0 (0) 0 (0) 1.000
Rejection grade ≥ 2R before
study entry, n (%)
1 (4.2) 5 (12.8) 0.256
Medications at study entry
Cyclosporine, n (%) 2 (8.3) 8 (20.5) 0.199
Tacrolimus, n (%) 22 (91.7) 31 (79.5) 0.199
Calcium channel blocker,
n (%)
19 (79.2) 30 (76.9) 0.835
ACE-I/ARB, n (%) 16 (66.7) 28 (71.8) 0.667
Antiplatelet drug, n (%) 20 (83.3) 38 (97.4) 0.044
Laboratory data at study entry
Triglycerides, mg/dL 109.0 (92.0–133.0) 94.0 (81.0–120.0) 0.067
Total cholesterol, mg/dL 157.4 ± 27.8 161.6 ± 42.2 0.664
LDL cholesterol, mg/dL 79.8 ± 24.8 86.3 ± 36.3 0.443
HDL cholesterol, mg/dL 53.2 ± 15.1 55.8 ± 13.1 0.468
HbA1c, % 5.2 (4.9–5.8) 4.9 (4.5–5.3) 0.019
Serum creatinine, mg/dL 0.96 (0.76–1.42) 0.84 (0.68–0.96) 0.092
eGFRa, (mL/min/1.73 m2) 80.6 (50.4–115.9) 96.9 (83.8–124.8) 0.087
Data are expressed as mean ± SD or median (IQR) for continuous values and number of
subjects (%) for categorical values.
ACE-I = angiotensin converting enzyme -inhibitor; ARB = angiotensin II receptor
blocker; BMI = body mass index; CMV = cytomegalovirus; D+/R- = donor CMV-posi-
tive/recipient CMV-negative; Cre = creatinine; eGFR = estimated glomerular ﬁltration
rate; EVL = everolimus; HbA1c = hemoglobin A1c; HDL = high density lipoprotein;
HTx = heart transplantation; ICM = ischemic cardiomyopathy; IQR = interquartile
range; LDL = low density lipoprotein; MDRD = modiﬁcation of diet in renal disease;
MMF=mycophenolate mofetil; PRA= panel reactive antibody; SD= standard deviation;
VAD= ventricular assist device.
a eGFR was calculated from creatinine value and the age, using the MDRD equation,
modiﬁed the Japanese coefﬁcient (0.881), as follows; eGFR (mL/min/1.73 m2) = 0.881 ∗
186 ∗ age−0.203 ∗ Cre−1.154 (for males), =0.881 ∗ 186 ∗ age−0.203 ∗ Cre−1.154 ∗ 0.742 (for
females).
Table 2
Statin therapy.
EVL group,
n = 24
MMF group,
n = 39
p value
Statin at study entry, n (%) 22 (91.7) 39 (100.0) 0.067
Strong statina, n (%) 13 (54.2) 13 (33.3) 0.103
High-dose statinb, n (%) 3 (4.2) 10 (25.6) 0.784
Statin at 1-year follow-up, n (%) 24 (100.0) 39 (100.0) 1.000
Strong statina, n (%) 18 (75.0) 15 (38.5) 0.005
High-dose statinb, n (%) 5 (20.8) 14 (35.9) 0.206
Switch to strong statin, n (%) 4 (16.7) 2 (5.1) 0.130
Intensive statin therapyc, n (%) 6 (25.0) 2 (5.1) 0.021
Data are expressed as number of subjects (%).
a Strong statins include atorvastatin, rosuvastatin, and pitavastatin.
b High-dose statins include doses of at least 20 mg/day for pravastatin, 20 mg/day for
atorvastatin, 5 mg/day for rosuvastatin, and 4 mg/day for pitavastatin.
c Intensive statin therapywas deﬁned as: (1) initiating statin therapy in recipients who
did not take statin at study entry, (2) increasing the statin dose between study entry and
the 1-year follow-up after entry, and (3) switching to a strong statin from pravastatin be-
tween study entry and the 1-year follow-up.
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decreased and PVI increased in the MMF group (p = 0.002 and 0.139,
respectively), and these changes resulted in a signiﬁcant increase in
%PVI (p = 0.006) and decrease in LVI (p b 0.001). In contrast, none of
the volumetric indices in the EVL group signiﬁcantly worsened at
1 year after EVL conversion.
With respect to changes in MIT, there was a greater increase in MIT
in the MMF group at the 1-year follow-up (p = 0.039), while MIT in
the EVL group did not change between study entry and the 1-year
follow-up (Table 3). TheMMF group had a higher incidence of increased
MIT (≥0.3 mm) (4.2% in the EVL group vs. 25.6% the MMF group,
p = 0.029, Fig. 3).
3.4. Logistic regression analysis for the changes in IVUS parameters
Changes in IVUSmeasurementswere treated as categorical variables
using the median value for the change in each IVUS measurement. Alogistic regression analysis was conducted to determine whether EVL
conversion was associated with changes in the volumetric IVUS indices
at the 1-year follow-up (Table 4). Univariate logistic regression analysis
showed that EVL conversion was associated with a smaller increase in
%PVI and a smaller reduction in LVI (p = 0.032 and p = 0.002, respec-
tively). After adjustment for the recipient's age, sex, strong statin use
at the 1-year follow-up, intensive statin therapy, and the time from
HTx to study entry, EVL conversion was signiﬁcantly associated with a
smaller increase in %PVI and a smaller reduction in LVI (p = 0.026
and p = 0.005, respectively, Table 4; Model 1). A multivariable logistic
regression analysis including EVL conversion, previous hypertension,
antiplatelet use at study entry, and intensive statin therapy revealed
that EVL conversionwas signiﬁcantly associated with a smaller increase
in %PVI and a smaller decrease in LVI (p= 0.044 and p= 0.017, respec-
tively, Table 4; Model 2). However, EVL conversion was not associated
with an individual change of VVI or PVI in the logistic regression analy-
sis. Regarding the inﬂuence of intensive statin therapy on changes in
volumetric IVUS parameters (Supplemental Table S1), intensive statin
therapy was signiﬁcantly associated with a smaller decrease in LVI
(p=0.046 inunivariate analysis and p=0.031 in themultivariate anal-
ysis of model 1).
3.5. IVUS measurements in the early and late cohorts
Recipients were divided into two subgroups according to study
entry timing (cutoff of 2 years after HTx, as summarized in Table 5).
CAV on IVUS was more developed in the EVL group at study entry in
each of the cohorts. The EVL group had 3-fold higher levels of PVI and
%PVI than those in the MMF group in the early cohort (p b 0.001) and
2-fold higher levels in the late cohort (PVI, p = 0.005; %PVI, p b
0.001). In the early cohort, theMMF group showed a marginal decrease
in VVI, resulting in amarginal increase in %PVI and a signiﬁcant decrease
in LVI (p= 0.035) by the 1-year follow-up. Signiﬁcant increases in MIT
between study entry and the 1-year follow-up were observed in the
MMF group (p= 0.041). In contrast, the EVL group did not showwors-
ening volumetric IVUS indices. In the late cohort, the MMF group
showed a signiﬁcant decrease in VVI (p = 0.015), resulting in signiﬁ-
cant increase in %PVI (p = 0.046) and a signiﬁcant decrease in LVI
(p=0.005) at the 1-year follow-up, whereas none of the volumetric in-
dices in the EVL group had signiﬁcantly worsened by 1 year after EVL
conversion.
3.6. Inﬂuence of EVL conversion for rejection and laboratory data
The incidence of cellular rejection before study entry was compara-
ble between the two groups (Table 1). During the course of the present
study, one recipient in the EVL group had Grade 2R rejection after
Table 3
IVUS measurements at study entry and 1-year follow-up.
EVL group, n = 24 MMF group, n= 39 p value
VVI, mm3/mm
Study entry 11.6 ± 3.0 11.8 ± 2.9 0.744
1-Year follow-up 11.4 ± 3.0 11.0 ± 2.8 0.583
p (entry vs. 1 year) 0.509 0.002
PVI, mm3/mm
Study entry 2.5 (1.8–3.4) 0.9 (0.6–1.7) b0.001
1-Year follow-up 2.4 (1.8–3.7) 0.9 (0.6–2.1) b0.001
p (entry vs. 1 year) 0.376 0.139
% PVI, %
Study entry 20.9 (17.2–27.2) 9.2 (4.8–14.0) b0.001
1-Year follow-up 22.3 (14.3–29.2) 9.8 (6.2–15.8) b0.001
p (entry vs. 1 year) 0.407 0.006
LVI, mm3/mm
Study entry 8.2 (7.2–10.3) 10.1 (8.7–12.0) 0.005
1-Year follow-up 8.3 (7.0–11.7) 9.0 (7.7–11.5) 0.203
p (entry vs. 1 year) 0.53 b0.001
MIT, mm
Study entry 1.31 (1.00–1.48) 0.56 (0.36–0.87) b0.001
1-Year follow-up 1.18 (0.94–1.44) 0.71 (0.39–1.10) b0.001
p (entry vs. 1 year) 0.166 0.039
Measured segment length, mm
Study entry 46.3 ± 8.1 45.9 ± 8.9 0.841
Data are expressed as mean ± SD or median (IQR) for continuous values.
EVL = everolimus; IQR = interquartile range; LVI = lumen volume index; MIT =
maximal intimal thickness; MMF = mycophenolate mofetil; PVI = plaque volume
index; %PVI= percent plaque volume index; SD= standard deviation; VVI = vessel vol-
ume index.
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biopsy and were treated with intravenous methylprednisolone. None
of the recipients experienced antibody-mediated rejection.
At the 1-year follow-up, lipid proﬁles were worse in the EVL
group (Table 6). Triglycerides values had increased by 23.6% in the
EVL group and decreased by 7.4% in theMMF group (p= 0.001). Fur-
thermore, the total cholesterol value had increased by 10.4% in the
EVL group but had decreased by 2.0% in the MMF group (p = 0.02).
However, EVL suppressed the deterioration of renal function
(serum creatinine value, a decrease of 7.9% in the EVL group vs. an in-
crease of 5.9% in the MMF group, p = 0.034; and eGFR value; an in-
crease of 5.8% in the EVL group vs. a decrease of 6.7% in the MMF
group, p = 0.015).
3.7. Adverse effects
In our study, we included recipients who could continue on EVL
for at least 1 year from initiation in the EVL group. One recipient
discontinued EVL because of joint pain and mouth ulcers and there-
after resumed MMF. Although two recipients had mild mouth sores
and three recipients had leukopenia, these recipients could continue
EVL.Fig. 3. Comparison of the incidence of greater increases inMIT between the EVL andMMF
groups. EVL = everolimus; MIT = maximal intimal thickness; MMF = mycophenolate
mofetil.4. Discussion
We evaluated the efﬁcacy of converting from MMF with standard-
dose CNIs to EVL with low-dose CNIs during the maintenance period
after HTx. This volumetric IVUS study demonstrated that (1) signiﬁcant
vessel shrinkage andmild increases in plaque volumewere observed in
the MMF group, resulting in a signiﬁcant increase in %plaque volume
and reduced lumen volume at the 1-year follow-up, whereas these
worsening changes in the IVUS indices indicating CAV progression
were not observed in the EVL group, and (2) EVL conversion was signif-
icantly associatedwith a smaller increase in percent plaque volume and
a smaller decrease in lumen volume. Furthermore, when subjects were
divided into sub-groups according to the timing of study entry, (3) the
suppressive effect of EVL on the development of CAV was observed in
both the early (b2 years after HTx) and late (≥2 years afterHTx) conver-
sion groups. These results suggest that EVL conversion reduces changes
in IVUS indices that indicate the development of CAV, even when initial
CAV has already been developed.
CAV is generally thought to be diffuse and to involve the entire cor-
onary artery [2]. In addition, lumen loss in CAV is caused not only by in-
timal thickening but also by changes in the external elastic membrane
area [23]. As 3D-IVUS versus standard 2D-IVUS analysis can investigate
the morphological changes in both the intima and the vessel in the en-
tire coronary artery with high sensitivity and accuracy [24], 3D-IVUS
analysis may enable more accurate evaluation of CAV progression.
Whether EVL conversion from MMF attenuates CAV development
during maintenance periods after HTx is still controversial [3,5–8].
Arora et al. [8], in a sub-study of 111 patients a mean 5.8 years after
HTx who participated in a multicenter, randomized controlled trial
with 2D-IVUS, showed that add-on EVL with reduced-dose CNIs did
not suppress CAV progression. However, Mancini et al. [3], in a single-
center study using 2D-IVUS in 46 subjects with severe CAV who were
randomly assigned to receive mTOR inhibitors a mean 3.3 years after
HTx, showed that conversion to rapamycin from MMF or AZA
attenuated CAV progression. Raichlin et al. [6], in a non-randomized,
retrospective study with 3D-IVUS in 69 subjects a mean of 3.8 years
after HTx, reported that progression of the plaque indexwas signiﬁcant-
ly smaller in the sirolimus group compared to the CNI group. Raichlin's
immunosuppressive regimens were conversion to sirolimus with com-
plete CNIwithdrawal. Here, our serial 3D-IVUS study demonstrated that
EVL conversion a mean 2.3 years after HTx attenuated the changes in
IVUS parameters that indicated CAV progression.
Arora et al. [8] showed that the suppressive effects of EVL on CAV
progression were different among concomitant immunosuppressants;
for example, concomitant AZA with EVL attenuated CAV progression,
whereas concomitant MMF with EVL was associated with accelerated
CAV. These results suggested the need to evaluate the effects of EVL
compared with individual immunosuppressant regimens. Previous
studies were limited by the fact that they compared mTOR inhibitors
to various immunosuppressants [6–8], whereas our observational
study could compare the recipients taking EVL conversion with those
with continuing MMF only. In addition, the majority of our recipients
took tacrolimus (84.1% of all subjects) instead of cyclosporine. In
contrast, EVL was primarily used with cyclosporine in most previous
studies [5,6,8]. Therefore, our results also suggest the beneﬁcial effect
of concomitant EVL with tacrolimus, not cyclosporine, on slowing the
development of CAV.
Although the impact of EVL on morphological changes of CAV
remains unclear, experimental studies have reported that mTOR inhib-
itors affect both vessel remodeling and neointimal proliferation [25,26],
which are the key components of CAV progression [23,27]. In our study,
the MMF group exhibited plaque progression and vessel shrinkage,
resulting in a signiﬁcant increase in %plaque volume and a signiﬁcant
decrease in lumen volume at the 1-year follow-up. In contrast, the EVL
group did not show these worsening changes of IVUS parameters.
Although EVL conversion was not associated with the individual
Table 4
Logistic regression analysis for changes in IVUS parameters.
Odds ratio of conversion to EVL (95% CI)
Univariate p value Model 1 p value Model 2 p value
%PVI (cut off ≥0.7%) 0.31 (0.11–0.91) 0.032 0.24 (0.07–0.84) 0.026 0.25 (0.07–0.97) 0.044
LVI (cut off ≥−3.9%) 6.00 (1.92–18.74) 0.002 8.69 (1.94–38.89) 0.005 5.14 (1.34–19.75) 0.017
VVI (cut off ≥−4.3%) 2.88 (0.99–8.31) 0.051 2.82 (0.86–9.27) 0.088 2.35 (0.65–8.42) 0.191
PVI (cut off ≥4.8%) 0.42 (0.15–1.19) 0.101 0.31 (0.09–1.04) 0.058 0.43 (0.12–1.55) 0.197
Model 1: adjusted for recipient age, sex, strong statin use at 1-year follow-up, intensive statin therapy and the time from heart transplantation to study entry.
Model 2: Multivariable logistic regression including variables with P b 0.05 in comparison between 2 groups as shown Table 1. (EVL conversion, previous hypertension, antiplatelet use,
HbA1c level, and intensive statin therapy).
CI= conﬁdence interval; EVL=everolimus; HbA1c=hemoglobin A1c; IVUS= intravascular ultrasound; LVI= lumen volume index; PVI=plaque volume index; %PVI=percent plaque
volume index; VVI = vessel volume index.
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ed in a signiﬁcant difference of changes in lumen volume and %plaque
volume. This result suggests that the impact of EVL conversion on
preventing both negative vessel remodeling and intimal proliferation
contributes to the suppressive effect on CAV progression. The mecha-
nisms of constrictive versus expansive remodeling are not well known
[28,29], but the ability to undergo compensatory vessel enlargement
in response to plaque growthhas been reported to bedependent on cor-
onary endothelial cell or smooth muscle cell function [30]. Previous
studies have shown that mTOR inhibitor vs. cyclosporine use was asso-
ciated with preserved coronary endothelial function and improved vas-
cular smooth muscle cell function in the transplanted artery [25,30,31].
The beneﬁcial effects of EVL on vessel remodeling in CAV may be one
mechanism by which EVL inhibits CAV progression in HTx recipients
in the maintenance period. Additionally, Potena et al. showed that a
greater increase in MIT (N0.35mm) 1 to 5 years post-HTx was associat-
ed with poor clinical outcomes more than 5 years after post-HTx [19].
Based on our results that the MMF group exhibited a greater incidence
of a larger increase in MIT (MIT ≥0.3 mm at the 1-year follow-up)
than did the EVL group, EVL conversion from MMF may contribute to
improvements in long-term outcome after HTx.
The appropriate timing of conversion to EVL has not yet been
established [3,5,8,10,11]. Since previous serial IVUS studies haveTable 5
IVUS measurements in sub-divided groups according to the study entry time from heart trans
Early b2 years
EVL group
n = 15
MMF group
n = 18
Time since HTx, year 0.9 (0.1–1.0) 0.2 (0.1–1.0)
VVI, mm3/mm
Study entry 12.0 ± 3.3 12.6 ± 3.3
1-Year follow-up 11.8 ± 3.2 11.8 ± 3.4
p (entry vs. 1 year) 0.521 0.062
PVI, mm3/mm
Study entry 2.5 (1.9–3.5) 0.8 (0.6–1.6)
1-Year follow-up 3.0 (2.1–3.9) 0.6 (0.59–1.6)
p (entry vs. 1 year) 0.999 0.199
% PVI
Study entry 21.3 (15.4–26.6) 7.4 (4.7–10.9)
1-Year follow-up 23.7 (15.8–37.2) 8.5 (5.0–11.1)
p (entry vs. 1 year) 0.955 0.071
LVI, mm3/mm
Study entry 8.5 (6.9–11.8) 10.8 (8.8–13.3)
1-Year follow-up 8.6 (7.1–11.8) 9.2 (8.0–12.5)
p (entry vs. 1 year) 0.91 0.035
MIT, mm
Study entry 1.3 (1.1–1.5) 0.4 (0.3–0.7)
1-Year follow-up 1.3 (1.1–1.5) 0.6 (0.4–0.9)
P (entry vs 1 year) 0.514 0.041
Measured segment length, mm
Study entry 44.3 ± 9.8 45.8 ± 9.4
Data are expressed as mean ± SD or median (IQR) for continuous values.
EVL = everolimus; IQR = interquartile range; LVI = lumen volume index; MIT = maximal i
percent plaque volume index; SD= standard deviation; VVI = vessel volume index.shown that CAV progresses faster in the early periods and later slows
[32–34], early initiation of EVL has been thought to be more effective
for preventing CAV progression compared with late initiation. Our
study demonstrated that late conversion (≥2 years after HTx) attenuat-
ed CAV development aswell as early conversion (b2 years after HTx). In
contrast, a recent retrospective study of 3D-IVUS in 52 recipients by
Masetti et al. [5] showed a conﬂicting result, in that late conversion to
EVL did not attenuate CAV progression compared with MMF, whereas
early EVL conversion did. They described that EVL exerted preventive
effects on CAV progression by antagonizing immune-mediated endo-
thelial cell injury, and EVL's efﬁcacy on CAV suppression might weaken
in the late periods after HTx because metabolic risk factors play a more
relevant role in favoring late CAV progression rather than immune-
mediated action. The exact mechanisms of the time-dependent effects
of mTOR inhibitors remain unclear. Importantly, a mechanism by
whichmTOR inhibitors attenuate CAV development has been explained
not only by a reduction in T-cell-mediated immunity but also by anti-
proliferative effects on vascular smooth muscle cell growth [27]. Prolif-
eration of smooth muscle and endothelial cells was induced by both
immune- and non-immune response mediated injury to endothelial
cells in the transplanted coronary artery [26,27]. Such proliferation is
known to be the ﬁnal common pathway in intimal hyperplasia, inde-
pendently of the cause of endothelial cell injury [27]. Therefore, EVL'splantation.
Late ≥2 years
p value EVL group
n = 9
MMF group
n = 21
p value
0.023 4.0 (3.0–4.6) 3.9 (3.0–5.0) 0.635
0.656 10.8 ± 2.6 11.2 ± 2.5 0.689
0.984 10.8 ± 2.6 10.4 ± 2.0 0.622
0.908 0.015
0.001 2.0 (1.7–3.2) 1.0 (0.6–1.7) 0.005
0.008 1.9 (1.8–2.3) 1.0 (0.8–2.3) 0.067
0.214 0.414
b0.001 20.1 (19.0–27.8) 10.6 (5.8–15.4) b0.001
0.002 18.4 (12.7–26.0) 13.5 (7.6–18.1) 0.060
0.173 0.046
0.047 7.5 (7.3–8.4) 10.0 (8.6–10.6) 0.013
0.159 8.2 (7.0–8.5) 8.7 (7.7–10.1) 0.483
0.214 0.005
b0.001 1.3 (0.9–1.4) 0.6 (0.4–1.0) 0.011
0.005 1.0 (0.9–1.2) 0.8 (0.5–1.2) 0.161
0.138 0.313
0.661 49.7 ± 1.0 45.9 ± 8.7 0.216
ntimal thickness; MMF = mycophenolate mofetil; PVI = plaque volume index; %PVI =
Table 6
The percent change of laboratory data at 1-year follow-up.
Variable EVL group, n = 24 MMF group, n = 39 p value
Triglycerides, % 23.6 (−0.7–54.9) −7.4 (−34.1–6.4) 0.001
Total cholesterol, % 10.4 ± 20.8 −2.0 ± 19.6 0.020
LDL cholesterol, % 13.0 ± 39.2 −3.7 ± 32.0 0.069
HDL cholesterol, % −2.2 (−20.1–16.5) 6.7 (−8.5–23.8) 0.322
HbA1c, % 8.2 ± 10.8 7.4 ± 10.9 0.773
Serum creatinine, % −7.9 (−14.5–12.4) 5.9 (−3.6–15.9) 0.034
eGFRa, % 5.8 ± 19.2 −6.7 ± 19.6 0.015
Data are expressed as mean ± SD, median (IQR).
Cre = creatinine; eGFR = estimated glomerular ﬁltration rate; EVL = everolimus;
HbA1c = hemoglobin A1c; HDL = high density lipoprotein; IQR = interquartile
range; LDL = low density lipoprotein; MDRD=modiﬁcation of diet in renal disease;
MMF = mycophenolate mofetil; SD = standard deviation.
a eGFR (mL/min/1.73 m2) was calculated from creatinine value and the age, using
the MDRD equation, modiﬁed the Japanese coefﬁcient (0.881), as follows; eGFR
(mL/min/1.73 m2) = 0.881 ∗ 186 ∗ age−0.203 ∗ Cre−1.154 (for males), =0.881 ∗ 186 ∗
age−0.203 ∗ Cre−1.154 ∗ 0.742 (for females).
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development independently of the timing of conversion. Another po-
tential reason for our discordant results comparedwith previous results
on late EVL conversion may be merely due to a bias of the larger differ-
ences in initial IVUS indices between the two groups. However, this bias
would generally lead us to underestimate the impact of EVL on CAV
progression.
In the present study, EVL conversion with reduced CNI did not in-
crease acute rejection and the deterioration of renal function. When
mTOR inhibitors are added with CNI, the toxic effects of CNI increase
[35]. Therefore, the use of mTOR inhibitors without CNIs has recently
emerged as an alternative therapeutic option for recipients with CNI-
induced nephropathy [6,7]. However, since one study reported that
the incidence of acute rejection was higher in recipients undergoing
conversion to SRL without CNIs [36], whether mTOR inhibitors with
CNI-free regimens is superior to mTOR inhibitors with reduced-dose
CNIs remains unclear. Our results also may provide evidence that EVL
conversion with a low-dose CNI regimen is feasible and safe for recipi-
ents with renal dysfunction.
The frequency of adverse effects of EVL was not high. On the other
hand, similar to the ﬁndings of previous studies [5,6], our results
showed that the lipid proﬁles in recipients were worsened.
5. Study limitations
Themain limitations of this studywere the small sample size and the
observational, retrospective design without randomization. Because of
this observational design, an indication bias could not be avoided.
Since one of the main reason for EVL conversion was the early develop-
ment of CAV as shown on IVUS, the incidence of CAV at study entry was
higher in the EVL group than in theMMF group. Therefore, we could not
fully compare the changes in IVUS indices between the EVL and MMF
groups. Finally, although CAV progression is known to be affected by
donor factors, we could not adjust for these variables in the multivari-
able model because of missing of donor information for recipients
who underwent HTx in other countries.
6. Conclusion
Our retrospective, observational study showed that conversion from
MMF with standard-dose CNIs to EVL with low-dose CNIs may reduce
the worsening change for IVUS indices that indicate CAV development.
Additionally, our results indicate that late conversion to EVL also may
reduce the worsening changes of IVUS indices. These results suggest
that EVL conversion is effective for slowing CAV progression when
CAV has already developed. In addition, this 3D-IVUS study suggests
that the suppressive effects of EVL on CAV progression may be inducednot only by reducing plaque progression but also by suppressing vessel
shrinkage.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2015.10.082.
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